Synaffix BV
Oss · Founded 2014
About Synaffix BV
Synaffix BV is a clinical-stage biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability. The company features technology offering (including 4 different ADC payloads) that enables the development of proprietary ADCs from any antibody and a patent portfolio provides patent protection of resulting Products through at least 2035. The company's technology employs an enzymatic modification of naturally occurring glycan anchor points found on all antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer molecules using extensively optimized metal-free click chemistry, allowing clinicians to design complex biological drugs without the need for prior genetic modifications.
Company Facts
- Founded: 2014
- Legal name: Lonza Group Ltd.
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Funding stage: M&A
- Last round: Series A (Feb 2014)
- Website: synaffix.com
- Phone: 31 24 365 2373
Social Profiles
Canonical: https://fsome.com/organization/synaffix-bv-8392242 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.